Related Experiment Video
Updated: Mar 19, 2026
11:17
Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
Published on: November 25, 2025
637
Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome
1Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. demail@springer.com.
Drugs
|June 22, 2016
Summary
Rotigotine transdermal patch provides continuous treatment for restless legs syndrome (RLS), showing significant symptom improvement and sustained efficacy. It is well-tolerated with a low risk of augmentation, offering a valuable therapeutic option.
Area of Science:
- Pharmacology
- Neurology
- Dermatology
Background:
- Restless Legs Syndrome (RLS) is a neurological disorder.
- Rotigotine is a dopamine agonist used for RLS treatment.
- Transdermal delivery offers continuous drug release, bypassing first-pass metabolism.
Purpose of the Study:
- To review the pharmacological properties of rotigotine transdermal patch.
- To evaluate the clinical efficacy and tolerability of rotigotine in RLS patients.
- To assess the long-term effects and safety profile of the treatment.
Main Methods:
- Review of pharmacological data.
- Analysis of short-term, 6-month, and extension studies.
- Evaluation of clinical efficacy (IRLS and CGI-S scores) and tolerability.
Main Results:
- Rotigotine patch significantly improved IRLS and CGI-S scores compared to placebo.
- Higher dosages (2 and 3 mg/24 h) showed greater efficacy.
- Efficacy was sustained for up to 5 years in extension studies.
- Common adverse events included application-site reactions, nausea, and headache.
- Low risk of RLS symptom augmentation was observed.
Conclusions:
- Rotigotine transdermal patch provides continuous, daily administration for RLS.
- It demonstrates significant efficacy and sustained therapeutic benefits.
- The patch is generally well-tolerated, similar to other non-ergolinic dopamine agonists.
- Rotigotine patch is a useful treatment option for patients with RLS.
Related Concept Videos
01:27Restless Leg Syndrome and Night Terrors
743
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
743
01:18Transdermal Drug Delivery Systems
105
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
105
01:15REM Sleep Behavior Disorder
2.3K
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
2.3K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.6K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.6K
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.2K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.2K